Efalizumab (Raptiva), an investigational therapy for moderate-to-severe psoriasis, achieved its primary efficacy endpoint in a randomized phase III study.
New Guidelines to Prevent Food Allergies in Pediatric Atopic Dermatitis Patients
The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques
25.1% of Patients Cited “Less Noticeable” Vitiligo in Recent Study
The Cutaneous Connection- Episode 35: QRPs and the Dermatology Practice
Indoor Tanning and Melanoma
Skin Barrier 101: Keep Up with What Your Patients Are Reading